UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

UPB UpStream Bio Inc.

休市中 09-11 16:00:00 EDT

5.73

-0.02

-0.35%

盘后5.73

+0.000.00%

19:30 EDT

最高5.84	最低5.65	成交量50.13万
今开5.84	昨收5.75	日振幅3.30%
总市值3.14亿	流通市值2.67亿	总股本5,477万
成交额287.12万	换手率1.07%	流通股本4,668万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":5.73,"timestamp":1789156800000,"preClose":5.75,"halted":0,"volume":501306,"hourTrading":{"tag":"盘后","latestPrice":5.73,"preClose":5.73,"latestTime":"19:30 EDT","volume":11114,"amount":63683.22,"timestamp":1789169407511,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0034782608695651434,"floatShares":46680775,"shares":54771041,"eps":-2.875781,"marketStatus":"休市中","change":-0.02,"latestTime":"09-11 16:00:00 EDT","open":5.84,"high":5.84,"low":5.65,"amount":2871151.911264,"amplitude":0.033043,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.875781,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":5.75,"postHourTrading":{"tag":"盘后","latestPrice":5.73,"preClose":5.73,"latestTime":"19:30 EDT","volume":11114,"amount":63683.22,"timestamp":1789169407511,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5917317194264232,"impliedVol":1.1803,"impliedVolPercentile":0.5458},"requestUrl":"/m/hq/s/UPB","defaultTab":"news","newsList":[{"id":"1137576544","title":"Upstream Bio在2026年ERS大会上口头报告Verekitug治疗重度哮喘的二期Valiant试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1137576544","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137576544?lang=zh_cn&edition=full","pubTime":"2026-09-08 15:35","pubTimestamp":1788852934,"startTime":"0","endTime":"0","summary":"UpStream Bio Inc.在2026年欧洲呼吸学会（ERS）大会上，通过口头报告的形式，对外公布了其候选药物Verekitug在治疗重度哮喘方面的二期Valiant临床试验数据。这场重要的学术报告吸引了众多呼吸领域专家的目光。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174103724","title":"Upstream Bio公布Verekitug针对重症哮喘与CRSwNP的关键性III期临床开发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1174103724","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174103724?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:01","pubTimestamp":1788260477,"startTime":"0","endTime":"0","summary":"Upstream Bio今日宣布，其核心在研药物Verekitug在重症哮喘及慢性鼻窦炎伴鼻息肉两大适应症上，均已锁定关键性III期临床开发路径。这一战略布局标志着该公司在呼吸与炎症疾病领域的研发管线迈入全新阶段。具体而言，Verekitug作为一款备受瞩目的候选疗法，其设计初衷直指重度哮喘患者群体中尚未被满足的迫切医疗需求。与此同时，针对CRSwNP这一同样困扰大量患者的慢性炎症性疾病，Upstream Bio亦同步规划了严谨的注册性试验方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117178706","title":"Upstream Bio在EAACI 2026大会上公布新应答者分析：Verekitug在二期VIBRANT试验中为绝大多数CRSwNP患者带来具临床意义的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1117178706","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117178706?lang=zh_cn&edition=full","pubTime":"2026-06-14 22:00","pubTimestamp":1781445620,"startTime":"0","endTime":"0","summary":"Upstream Bio公司于2026年欧洲过敏与临床免疫学会大会上，公布了其候选药物Verekitug在二期VIBRANT试验中的最新应答者分析数据。结果显示，在接受Verekitug治疗的患者中，绝大多数患有慢性鼻窦炎伴鼻息肉的参与者，其病情获得了具有临床意义的显著改善。这项深入分析进一步证实了Verekitug作为一款潜在疗法的积极信号。此次在EAACI这一权威国际会议上展示的数据，增强了Verekitug在治疗CRSwNP这一领域的前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123552714","title":"上游生物将在EAACI 2026口头报告环节展示Verekitug针对CRSwNP的二期Vibrant试验额外疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123552714","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123552714?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:00","pubTimestamp":1780916426,"startTime":"0","endTime":"0","summary":"上游生物公司计划在即将举行的欧洲过敏与临床免疫学会2026年大会上，通过口头报告形式，进一步公布其候选药物Verekitug用于治疗慢性鼻窦炎伴鼻息肉病的二期Vibrant临床试验的额外疗效数据。此次展示旨在向科学界提供关于该疗法潜力的更深入见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104582898","title":"Upstream Bio在ATS 2026国际会议上公布Verekitug二期Vibrant试验新数据，显示其改善CRSwNP合并哮喘患者的哮喘症状控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1104582898","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104582898?lang=zh_cn&edition=full","pubTime":"2026-05-18 23:30","pubTimestamp":1779118224,"startTime":"0","endTime":"0","summary":"Upstream Bio在2026年美国胸科学会国际会议上，公布了其候选药物Verekitug在二期Vibrant临床试验中的最新数据。数据显示，对于同时患有慢性鼻窦炎伴鼻息肉和哮喘的患者，Verekitug在改善哮喘症状控制方面展现出积极效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162420003","title":"Upstream Bio公布Verekitug三期临床试验战略及2025年第四季度与全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1162420003","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162420003?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:03","pubTimestamp":1774523017,"startTime":"0","endTime":"0","summary":"生物制药公司Upstream Bio近日宣布了其核心候选药物Verekitug的三期临床开发战略，并同步披露了2025年第四季度及全年的财务报告。此次公布标志着Verekitug的研发进入关键阶段，公司对其未来市场前景充满信心。财务数据则反映了公司在研发投入与业务运营方面的最新状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486705257","title":"单月超6亿美元，医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来，生物医药领域已经有30家公司IPO上市，累计融资规模超40.49亿美元，其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域，阿斯利康以总价18亿美元收购AmolytPharma，获得了处于临床3期的PTH1R激动剂eneboparatide，目前该疗法已经获得了FDA快速通道认定，另一家药企AscendisPharma的Yorvipath获得FDA批准上市，用于治疗成人慢性甲状旁腺功能减退。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSQ","BK4599",".IXIC","MNQmain","BK4539","SEPN","NQmain","BK4020","SQQQ","BK4561","TSLP","BK4200","QLD","UPB","BK4139","QID","ASO","GPCR","BK4007","BDMD","CAMP","APGE","GLYC","SYRS","AVTE","TQQQ","BK4082","OMGA"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.upstreambio.com","stockEarnings":[{"period":"1week","weight":-0.0466},{"period":"1month","weight":-0.1708},{"period":"3month","weight":-0.0607},{"period":"6month","weight":-0.3792},{"period":"1year","weight":-0.6802},{"period":"ytd","weight":-0.789}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Upstream Bio, Inc.于2021年4月21日在特拉华州注册成立。他们是一家临床阶段的生物技术公司，开发炎症性疾病的治疗方法，最初专注于严重的呼吸系统疾病。他们正在开发verekitug，这是目前临床开发中唯一已知的拮抗剂，靶向胸腺间质淋巴细胞生成素（“TSLP”）受体，TSLP是一种细胞因子，是临床验证的炎症反应驱动因素，位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明，verekitug对TSLP受体具有高度有效的抑制作用，这将转化为差异化的产品特征，包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。","exchange":"NASDAQ","name":"UpStream Bio Inc.","nameEN":"UpStream Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"UpStream Bio Inc.,UPB,UpStream Bio Inc.股票,UpStream Bio Inc.股票老虎,UpStream Bio Inc.股票老虎国际,UpStream Bio Inc.行情,UpStream Bio Inc.股票行情,UpStream Bio Inc.股价,UpStream Bio Inc.股市,UpStream Bio Inc.股票价格,UpStream Bio Inc.股票交易,UpStream Bio Inc.股票购买,UpStream Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}